Lin Zhang is a Neurology physician affiliated with UC Davis Health. OpenAlex indexes 40 publications with 1,284 citations (h-index 16); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4860 Y St
Sacramento, CA 958172307
Telephone
916-734-3588Registry record last updated 8 Jul 2007.
Clinical trials
- Phase I Clinical Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of LYN101
Sponsor: Shanghai TTM-Bio Technology Co., Ltd
- Safety, Tolerability and Exploratory Efficacy of EC5026 in Parkinson's Disease (STEP Study)
Sponsor: EicOsis Human Health Inc.
- To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women With Osteoporosis at High Fracture Risk
Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
14 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- MDD US Operations, LLCProgram year202541 payments$39,224openpaymentsdata.cms.gov ↗
- ORPHALAN INCProgram year20251 payment
- Boston Scientific CorporationProgram year20255 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
5 NIH research awards on record, funded 2023–2026 per NIH RePORTER. The latest:
- Therapeutic mechanisms of targeting WRN in MSI colorectal cancer.
University of Southern California
FY2026$581,548R01CA312130 - Role of p73-mediated DR5 induction in therapeutic response to CDK inhibition.
University of Southern California
FY2026$560,863R01CA311678 - BET degraders for improving colorectal cancer therapy
University of Southern California
FY2025$438,915R01CA248112
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Donald Hilty, MD, MBA
UC Davis Health
William Pevec, MD
UC Davis Health
Ankit Sarin, MD, MHA
UC Davis Health
Herman Hedriana, MD
UC Davis Health
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”